Tranexamic acid in trauma: How should we use it?

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S195-S199

  Roberts, I ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Clinical trial; Fibrinolysis; Surgery; Tranexamic acid; Wounds and injuries

Indexed keywords

TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

BLEEDING; BLOOD TRANSFUSION; BRAIN SURGERY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FIBRINOLYSIS; HUMAN; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TRAUMATIC BRAIN INJURY; TREATMENT INDICATION; ANIMAL; COMPLICATION; DRUG EFFECTS; HEMORRHAGE; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; WOUNDS AND INJURIES;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; FIBRINOLYSIS; HEMORRHAGE; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TRANEXAMIC ACID; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 84931400097     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12878     Document Type: Review

References (23)

1. Cesarman-Maus G, Hajjar K. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.
2. Lucas M, Fretto L, McKee P. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-56.
3. Takada A, Makino Y, Takada Y. Effects of tranexamic acid on fibrinolysis, fibrinogenolysis and amidolysis. Thromb Res 1986; 42: 39-47.
4. Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, Miles LA. Regulation of macrophage migration by a novel plasminogen receptor Plg-RKT. Blood 2011; 118: 5622-30.
5. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 2008; 118: 3012-24.
6. Busuttil SJ, Ploplis VA, Castellino FJ, Tang L, Eaton JW, Plow EF. A central role for plasminogen in the inflammatory response to biomaterials. J Thromb Haemost 2004; 2: 1798-805.
7. Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR 3rd, Parmer RJ, Miles LA. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood 2010; 115: 1319-30.
8. Syrovets T, Jendrach M, Rohwedder A, Schüle M, Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKb-mediated NF-kB activation. Blood 2001; 97: 3941-50.
9. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012; 344: e3054.
10. Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. B J Surg 2013; 100: 1271-9.
11. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
12. Ker K, Kiriya J, Perel P, Edwards P, Shakur H, Roberts I. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med 2012; 12: 3.
13. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T.The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096-101.
14. Roberts I, Prieto-Merino D, Manno D. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Crit Care 2014; 18: 685.
15. Roberts I, Perel P, Prieto-Merino D, Shakur H, Coats T, Hunt BJ, Lecky F, Brohi K, Willett K, CRASH-2 Collaborators. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ 2012; 345: e5839.
16. Pealing L, Perel P, Prieto-Merino D, Roberts I. Risk factors for vascular occlusive events and death due to bleeding in trauma patients; an analysis of the CRASH-2 cohort. PLoS ONE 2012; 7: e50603.
17. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS ONE 2011; 6: e18987.
18. Chapman M, Moore E, Ramos C, Ghasabyan A, Harr J, Chin T, Stringham J, Sauaia A, Silliman C, Banerjee A. Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg 2013; 75: 961-7.
19. Napolitano L, Cohen M, Cotton B, Schreiber M, Moore E. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg 2013; 74: 1575-86.
20. Perel P, Prieto-Merino D, Shakur H, Clayton T, Lecky F, Bouamra O, Russell R, Faulkner M, Steyerberg EW, Roberts I. Predicting early death in patients with traumatic bleeding: development and validation of prognostic model. BMJ 2012; 345: e5166.
21. Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005; 15: 302-8.
22. Dewan Y, Komolafe EO, Mejia-Mantilla JH, Perel P, Roberts I, Shakur H. CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012; 13: 87.
23. Renckens R, Weijer S, De Vos AF, Pater JM, Meijers JC, Hack CE, Levi M, van der Poll T. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004; 24: 483-8.